1340 NDI-101150 is a potent and highly selective hematopoietic progenitor kinase 1 (HPK1) inhibitor that promotes a robust and broad anti-tumor immune response by Scott Daigle, David Ciccone, Samantha Carreiro, Christine Loh, Neelu Kaila, Fu-Shan Kuo, Scott Boiko, Gene Yau, Esha A Gangolli, Denise Levasseur, Bhaskar Srivastava, Frank G Basile

751 Monotherapy results from an ongoing phase 1a dose escalation study of NDI-101150, a highly selective oral hematopoietic progenitor kinase 1 (HPK1) inhibitor by Scott Daigle, Sunil Sharma, Xinyan Zhang, Martin Gutierrez, Patricia Fraser, David Sommerhalder, Scott Boiko, Esha A Gangolli, Bhaskar Srivastava, Frank G Basile, Marcus Noel, Amanda Hoerres, Nawaid Rana, Rama Balaraman

Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial by Seung Tae Kim, Sujin Lee, Minhwa Park, Se Hoon Park, Joon Oh Park, Ho Yeong Lim, Young Suk Park, Won Ki Kang, Esha A. Gangolli, Hyeongchan Shin, Kyoung-Mee Kim, Simon J. Hollingsworth, Peter G.S. Mortimer, Jeeyun Lee

Get full text